|
pubmed:otherAbstract |
PIP: Glucose tolerance was studied using the standard oral test in 61 patients taking cyclic estrogen-progestin combinations for a period of 3 months to 7 years. 27 women were on cyclic mestranol-norethynodrel in 10 mg doses, 5 were on 5 mg doses, 16 were on cyclic mestranol-ethynodiol diacetate in 1 mg and 12 in 2 mg doses, 1 was on norethindrone. Decreased tolerance was observed in 39% of the study group with 18% having diabetic tolerance curves. Follow-up studies were conducted over a period of 3 to 28 months and variable results were obtained. The mechanism of decreased glucose tolerance is unknown. There is no accurate means of predicting which patient will develop decreased tolerance while on cyclic estrogen-progestin therapy.
|
